Our latest product, γ-Secretase Inhibitor XXI, utilizes the innovative Compound E mechanism. It is backed by extensive research and has a CAS number of 209986-17-4.
Treatment options for Alzheimer's disease and the use of γ-Secretase inhibitors in the field of neuroscience.
Other products in the same category include Semagacestat, Avagacestat, and BMS-708163.
Advantages for Health: Secretase Inhibitor XXI (Compound E) principally provides prospective therapeutic advantages in the setting of Alzheimer's disease and other neurodegenerative disorders. Alzheimer's disease progression is significantly influenced by the metabolism of amyloid precursor protein (APP).
Possible Effects: Possible Outcomes: Neuroprotective benefits, delaying the onset of Alzheimer's disease, and decreased generation of amyloid-beta peptides.
How Products Work: Compound E has the ability to block the γ-secretase complex, which is an essential enzyme involved in the production of amyloid-beta peptides from amyloid precursor protein (APP). By suppressing this process, it may diminish brain amyloid-beta plaques, which cause neurodegeneration in Alzheimer's disease.
Safety: Because Compound E is a research compound, its safety profile is mainly established via clinical and laboratory investigations. Long-term safety data is currently being investigated.
Adverse Effects: The following are the most frequently documented adverse effects in scientific investigations:
Mood changes, rashes, and possibly liver damage being caused.
Information on dosing: How much γ-Secretase Inhibitor XXI is given depends on the particular study or treatment setting. In clinical research, doses often vary from low micromolar concentrations to those that are much higher.
Known hypersensitivity to any formulation component, pregnancy, breastfeeding, and severe liver impairment are contraindications.
In conclusion, γ-Secretase Inhibitor XXI (Compound E) shows great promise for Alzheimer's research because of its ability to control the synthesis of amyloid-beta. However, its clinical use demands more study to properly grasp its effectiveness and safety profile.
"People Also Ask" Section: Q: Is it possible for γ-Secretase Inhibitor XXI to treat Alzheimer's disease? Q: It is not a cure for Alzheimer's disease, but it may help lower amyloid-beta formation, which is a major problem. There is still a significant amount of study being done on its effectiveness and long-term advantages.
Q: Is Compound E long-term safe? A: Research is now being done on Compound E's long-term safety profile. It is mostly used in restricted research settings.
Regarding additional neurological disorders, is this compound applicable? Q: Although it has been developed mainly for Alzheimer's disease, studies are being conducted to see whether it may be used for other types of neurodegenerative diseases.
What sets Compound E different from other γ-Secretase inhibitors? A: The unique inhibitory activity and potency of compound E set it apart. Comparative investigations with different inhibitors are required to understand its unique features.
